# Etnova Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/etnova-therapeutics-co

- Industry: Biotechnology
- Headquarters: Suwon, South Korea
- Website: www.etnova.co.kr
- Total disclosed funding: $4.2M
- Latest round: Series A (Apr 7, 2022)
- Investors on record: 6

## About

Based in South Korea, and founded in 2020, Etnova Therapeutics Co. Ltd., operates as a developer of low-molecular synthetic medicines for hepatocellular carcinoma cancer. In April 2022, Etnova Therapeutics Co. Ltd. raised KRW 52 billion in series A funding co-led by new investors Albatross Investment and Musk Healthcare, with the participation of other new investors Enlite Ventures, HYK Partners, Fiez Investment, and IPS Ventures. As of 2022, Jang Sa-Jeong acts as the CEO of the company.

The company offers various drugs that treat liver cancer including MBP-1190 used for the treatment of hepatocellular carcinoma cancer. The company is also working on the development of a new drug, MBP-11901.

The company plans to use the April 2022 funding to expand its operations and further develop its platform's technology.

## Funding rounds

- Series A, Apr 7, 2022, $4.2M — Albatross Investment, Enlight Ventures, Golden Oak Investment, IPS Ventures, Fiez Investment, Musk Healthcare

## Investors

- Albatross Investment (https://capitalatlas.ai/funds/albatross-investment) — Series A
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Series A
- Golden Oak Investment (https://capitalatlas.ai/funds/golden-oak-investment) — Series A
- IPS Ventures (https://capitalatlas.ai/funds/ips-ventures) — Series A
- Fiez Investment — Series A
- Musk Healthcare — Series A